Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (tsc)

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Auricchio, Neil ^a   Malinowska, Izabela ^a   Shaw, Reuben ^b   Manning, Brendan D ^c   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; METFORMIN; PARAFFIN; RAPAMYCIN; SUCROSE; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYSTADENOMA; DRUG EFFICACY; DRUG TARGETING; EXPERIMENTAL MOUSE; HAMARTOMA; KIDNEY CYSTADENOMA; MARKER GENE; MOUSE; NONHUMAN; PHARMACODYNAMICS; QUANTITATIVE STUDY; STAINING; TREATMENT DURATION; TSC2 GENE; TUBEROUS SCLEROSIS; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; BODY WEIGHT; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; BODY WEIGHT; BORONIC ACIDS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES, CYSTIC; KIDNEY NEOPLASMS; METFORMIN; MICE; PYRAZINES; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 84857416727     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031900     Document Type: Article

References (31)

1. Kwiatkowski DJ, Thiele EA, Whittemore VH, (2010) Tuberous sclerosis complex Weinheim, Germany Wiley-VCH.
2. Huang J, Manning BD, (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412: 179-190.
3. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
4. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
5. Yecies JL, Manning BD, (2011) mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med 89: 221-228.
6. Kwiatkowski DJ, Manning BD, (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14 Spec No. 2: R251-258.
7. Franz DN, Leonard J, Tudor C, Chuck G, Care M, et al. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59: 490-498.
8. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140-151.
9. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801-1811.
10. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, et al. (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364: 1595-1606.
11. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, et al. (2008) Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29: 541-551.
12. Williamson MJ, Silva MD, Terkelsen J, Robertson R, Yu L, et al. (2009) The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models. Mol Cancer Ther 8: 3234-3243.
13. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M, (2006) Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 3: 374-387.
14. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL, (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538.
15. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
16. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
17. Inoki K, Zhu T, Guan KL, (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
18. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646.
19. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, et al. (2011) Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 154: 602-613.
20. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, et al. (2010) Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 3: 1066-1076.
21. Huang X, Wullschleger S, Shapiro N, McGuire VA, Sakamoto K, et al. (2008) Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412: 211-221.
22. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ, (1999) Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 104: 687-695.
23. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D, (2009) Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8: 38.
24. Vavvas D, Apazidis A, Saha AK, Gamble J, Patel A, et al. (1997) Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP-activated kinase in skeletal muscle. J Biol Chem 272: 13255-13261.
25. Li C, Chen S, Yue P, Deng X, Lonial S, et al. (2010) Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 285: 16096-16104.
26. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, et al. (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42: 213-227.
27. Kenerson H, Dundon TA, Yeung RS, (2005) Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57: 67-75.
28. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
29. Walter P, Ron D, (2011) The unfolded protein response: from stress pathway to homeostatic regulation. Science 334: 1081-6.
30. Engelman JA, Cantley LC, (2010) Chemoprevention meets glucose control. Cancer Prev Res (Phila) 3: 1049-1052.
31. Feldman JP, Goldwasser R, Mark S, Schwartz J, Orion I, (2009) A mathematical model for tumor volume evaluation using two-dimensions. J Appl Quant Methods 4: 455-462.